

## Correlation between Serum Vitamin D Levels and BODE Index in COPD Patients in A Tertiary Care Centre

Laxma Reddy S<sup>1</sup>, Bhaskar K<sup>2\*</sup>, Vara Prasad K<sup>3</sup>, Paramjyothi GK<sup>4</sup>

<sup>1</sup>Senior Resident, Department of Pulmonary Medicine, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad, Telangana 500082, India

<sup>2</sup>Associate professor, Department of Pulmonary Medicine, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad Telangana 500082, India

<sup>3</sup>Junior Resident, Department of Pulmonary Medicine, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad Telangana 500082, India

<sup>4</sup>Professor and HOD, Department of Pulmonary Medicine, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad Telangana 500082, India

### Original Research Article

\*Corresponding author

Bhaskar K

#### Article History

Received: 12.03.2018

Accepted: 25.03.2018

Published: 30.03.2018

#### DOI:

10.36347/sjams.2018.v06i03.093



**Abstract:** Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease and a major cause of disability and death all over the world. A multidimensional scale, the BODE index [BMI (B), degree of airflow obstruction (O), dyspnea as measured by the MRC dyspnea scale (D), and exercise capacity (E)] has been validated and proven to be useful in predicting two year mortality. Vitamin D deficiency is commonly seen in COPD patients. This study conducted in a tertiary care hospital has focused on the relationship between serum vitamin D levels and BODE index. A cross sectional observational study was performed at Nizam's Institute Of Medical sciences, a tertiary care hospital in Hyderabad, Telangana during the period of 2015-2017. This study included 104 COPD cases attending outpatient department of pulmonary medicine. Among 104 patients, 87 were males and 17 were females. The mean Vitamin D value of the study population was 20.77ng/ml ( $\pm 11.74$ ). Most of the patients (60%) had BODE index score < 5. The mean BODE index score decreased as the degree of vitamin D deficiency increases. Serum vitamin D deficiency is present in majority of COPD patients. It is more prevalent among patients with higher COPD GOLD Stages. There appears to be a positive correlation between serum vitamin D levels and post bronchodilator FEV1 (%). Vitamin D deficiency was found to be positively correlated with 6 minute walk distance. There is significant correlation between serum vitamin D deficiencies and BODE index.

**Keywords:** COPD, vitamin D, BODE index, BMI, FEV1, 6MWD, Dyspnea scale.

## INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and death all over the world. It is responsible for a huge social and economic burden for the health care infrastructure. COPD is the fourth leading cause of death in the world [1], represents an important public health challenge that is both preventable and treatable. According to World Health Organization estimates, 65 million people have moderate to severe COPD. More than 3 million people died of COPD in 2005 corresponding to 5% of all deaths globally [2].

According to the Global Obstructive Lung Disease (GOLD) guidelines Chronic Obstructive Pulmonary Disease (COPD) is defined as a common, preventable and treatable disease that is characterized

by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

There is no sufficient data estimating the prevalence of COPD in India, crude estimates suggest there are 30 million COPD patients in India [3]. COPD is a lung disease associated with significant and progressive irreversible airflow obstruction [4]. The strongest risk factor for COPD and an accelerated decline in adult lung function is cigarette smoking, and smoking cessation is known to slow the rate of decline of lung function [5,6,7]. Other factors that increase the burden of inhaled particulates and are associated with increased oxidative stress in the lungs including outdoor and indoor air pollution, and occupation [8,9],

A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production and a history of exposure to the above said risk factors for the disease. Spirometry is required to make the diagnosis in this clinical context. Airflow limitation is best measured by Spirometry, a reproducible test of lung function. The presence of a post-bronchodilator FEV<sub>1</sub>/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD.

Vitamin D plays a role in large number of biological processes, and that reduced levels of this hormone are implicated in a range of diseases. Vitamin D involved in the regulation of 3% of the human genome. Two genes containing the target sequence indicative of vitamin D regulation are those encoding LL-37 (cathelicidin) and hBD-2. These antimicrobial peptides are integral components of the innate immune system and act as natural antibiotics to help combat infection [10,11]. In 1922 Elmer V. McCollum identified an antirachitic substance in cod liver oil and called it Vitamin D [12]. Study of the physiological importance of vitamin D is a field which is expanding rapidly, with deficiencies of vitamin D giving an insight into many new roles. A recent meta-analysis of randomized controlled trials concluded that use of vitamin D supplements is associated with a decrease in total mortality rates [13]. Specifically in respiratory health, vitamin D deficiency has been shown to

- Increase the risk of upper respiratory tract infections and to decrease the forced expiratory Volume in 1 s (FEV<sub>1</sub>) in asthma and wheezing disease [14]
- It also helps the remodeling of airways and reverses steroid resistance which are important Characteristics of COPD [15]

Interest in this area has grown further following the results of a large population survey in the United States, which observed a dose–response relationship between Vitamin D status and FEV<sub>1</sub> [16]. Higher vitamin D concentrations have been associated with better lung function as measured by forced expiratory volume in 1 s (FEV<sub>1</sub>) in a large cross-sectional study of the U.S. population in the NHANES II study[17].

Celli and colleagues evaluated 207 patients with COPD and identified 4 easily measured variables that predicted an elevated risk for death: BMI (B), degree of airflow obstruction (O), dyspnea as measured

by the MRC dyspnea scale (D), and exercise capacity (E) as measured by the 6MWD test [18]. These variables were used to construct a multidimensional scale, the BODE index, that ranged from 0 (least risk) to 10 (highest risk). Furthermore, in clinical studies comparing the BODE Index with FEV<sub>1</sub>, the BODE Index was shown to better assess progression of disease secondary to COPD exacerbations [19] and to be a significantly better predictor than the FEV<sub>1</sub> for the risk for hospitalization due to exacerbations [20]. Therefore this study was performed to see the relationship between serum Vitamin D levels and BODE index.

**METHODS**

This cross sectional Observational study performed in the Department of Pulmonary Medicine, Department of Biochemistry, Nizam’s Institute of Medical Sciences (NIMS), Hyderabad, and Telangana. Total 104 stable COPD patients were recruited from *1st January 2015 to 30th June 2016. Patients aged 35 years or more with history suggestive of COPD (cough with sputum production in chronic bronchitis and breathlessness in emphysema), and spirometry confirmed diagnosis of COPD as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, (only those patients who have a post bronchodilator FEV<sub>1</sub>/FVC ratio of less than 70%) were included.*

**EXCLUSION CRITERIA**

- Current or past diagnosis of asthma (defined as an increase in FEV<sub>1</sub> >12% and > 200 mL above the baseline value after administration of a bronchodilator).
- Inability to complete the lung function test or 6-minutes walking distance (6MWD) test.
- All patients with insufficient mental capacity that preclude obtaining an informed consent from them.
- Patients are excluded if they have TB, active cancer, diabetes, hypertension, CAD, CKD and liver failure.
- Patients who are on oral glucocorticoid therapy.

A detailed history of patient is taken & physical examination of each case done. Body mass index (BMI) calculation, Dyspnoea scoring according to modified medical research council (mMRC), 6 minute walk distance test was done and BODE index is calculated (Table 1). Hemogram, Serum vitamin D levels, Spirometry, Renal function tests, Liver function tests, Chest radiograph were done. Additional investigations may also be done depending on the patient’s requirement.

**Table-1: Calculation of BODE index**

Parameters	Points on BODE index			
	0	1	2	3
FEV1(% of predicted)	≥65	50-64	36-49	≤35
Distance walked in 6 minutes(m)	≥350	250-349	150-249	≤150
Dyspnea scale score(mMRC)	0-1	2	3	4
Body mass index(BMI)	>21	<21		

SPSS statistics 17.0 version used for data analysis. Results were given as mean  $\pm$  SD for data with normal distribution and variables that are not normally distributed will log-transformed (median and interquartile range [IQR]). The between-group differences calculated using a two-sided paired t-test or Chi-squared statistic where appropriate. To analyse relationships between variables, Student t test and simple regression performed. A p-value  $<0.05$  will be

considered statistically significant.

**RESULTS**

Total 104 stable COPD patients were recruited during study period.

87 were males and 17 were females of total 104 indicating male dominance (Table-2).

**Table-2: Gender distribution of study population**


Gender	Frequency(n)	Percentage
Male	87	83.6%
female	17	16.4%
Total	104	100%

**Table-3: Age distribution of study population**


Age(years)	Frequency(n)	Percentage
30-40	2	1.90%
40-50	10	9.61%
50-60	28	26.92%
60-70	46	44.2%
70-80	16	15.3%
>80	2	1.90%
TOTAL	104	100%

Age is ranged from 38 years to 91 years. Most of the patients were in age group between 60-70 years. About 60% patients were aged more than 60 years.

Mean BMI was 26.40 ( $\pm 5.77$ ) kg/m<sup>2</sup>. Minimum BMI was 14.9 kg/m<sup>2</sup> and maximum BMI was 36.5 kg/m<sup>2</sup>. Most of the population had normal BMI within the range of 18.5-25kg/m<sup>2</sup> (49.0%). 7 patients (6.7%) were obese with BMI  $>30$  kg/m<sup>2</sup> (Fig-1).




**Fig-1: BMI status of study population**



**Fig-2: Distribution of study population as per FEV1**

Majority of patients (71%) had FEV1 value between 36-64 (% of predicted). 27% of patients had

FEV<sub>1</sub> of  $\geq 65$  (% of predicted). 1% of patients had FEV<sub>1</sub> of  $\leq 35$  (% of predicted).




**Fig-3: Frequency distribution of 6MWD**

In 5 (4.80%) patients 6 minute walk distance was less than 150 meters. In 37 (35.57%) patients 6 minute walk distance was >350 meters. In most of

patients (60.0%) 6 minute walk distance was between 150-350 meters.

Majority of patients had grade 3 mMRC breathlessness. None had grade 4 (Fig-4).




**Fig-4: Frequency distribution of 6MWD**

**Table-4: Frequency distribution of vitamin D status**

Vitamin D status	Frequency	Percentage
Sufficient (> 30 ng/ml)	32	30.7%
Deficiency (>10 to ≤30 ng/ml)	42	44.2%
Severe Deficiency (≤10 ng/ml)	26	25.0%
Total	104	100%

The mean Vitamin D value of the study population was 20.77 ng/ml (±11.74) .Minimum vitamin D levels was 5.6 ng/ml and maximum value

was 43.9 ng/ml. Majority of the COPD patients were vitamin D deficient (69.2%).25.0 % was severely deficient of vitamin D.



**Fig-5: Vitamin D levels vs BODE score**

BODE index score ranged from 0 to 9. Most of the patients (60) were had BODE index score < 5. The mean BODE index score increased as the degree of vitamin D deficiency increases. (7.57 ± 1.60>3.94 ± 2.10 >1.96 ±1.22)(P<0.001).

**DISCUSSION**

In this single institution based, observational cross sectional study, conducted for one and half year time period 104 COPD patients were recruited. Age ranged from 38 years to 91 years. Most of the study

population 64(60.0%) was above 60 years of age where 87(83.6%) patients were male and 17(16.4%) participants were female (Table 2&3).

Mean, minimum and Maximum BMI were 26.40 ( $\pm 5.77$ ) kg/m<sup>2</sup>, 14.9 kg/m<sup>2</sup> and 36.5 kg/m<sup>2</sup> respectively. Most of the population had normal BMI within the range of 18.5-25kg/m<sup>2</sup> (49.00%). 7 patients (6.72%) were obese with BMI >30 kg/m<sup>2</sup> (Figure 1).

The mean Vitamin D value of the study population was 20.77 ng/ml ( $\pm 11.74$ ). Minimum vitamin D level was 5.6 ng/ml and Maximum value was 43.9 ng/ml. Majority of the COPD patients were vitamin D deficient (69.2%). 25 % were severely deficient (Table 4).

Our study showed that both prevalence and severity of vitamin D deficiency in stable COPD patients increase as the disease severity progresses. Prevalence of serum vitamin D deficiency in GOLD Stage 1 was 30%, Stage 2 was 87.5%, and Stage 3 and 4 was 100%.

When compared to other studies, our study has higher prevalence of vitamin D deficiency. Similar analysis was done by Jansen's W. *et al.* [21] in 2010 showed 39%, 47%, 60% and 77% of patients deficient of vitamin D among GOLD stages 1, 2, 3 and 4 respectively and he concluded that vitamin D deficiency becomes more common as COPD GOLD stages become higher. We found the mean value of serum vitamin D decreases along with increase severity of COPD. The mean serum vitamin D level was 30.82 ng/ml among patient in GOLD Stage 1 and it was 10.05( $\pm 5.38$ ) ng/ml in GOLD Stage 4.

Post bronchodilator FEV<sub>1</sub> (%) value, a measurement of severity of airway obstruction, decreases as the level of mean serum vitamin D become decreased. The mean FEV<sub>1</sub>% was 83.15 $\pm$ 11.53, 60.97 $\pm$ 17.47, 30.71 $\pm$ 7.96 amongst vitamin D sufficient, deficient and severe deficient groups respectively (Figure 2). We concluded that there is a positive correlation between serum vitamin D level and post bronchodilator FEV<sub>1</sub> (%) volumes (p <0.01). Similarly, Mohamad monandi *et al.* [22] measured the serum 25-hydroxyvitamin D (25-OHD) and post bronchodilator forced expiratory volume in 1s (FEV<sub>1</sub>). The mean FEV<sub>1</sub> volume (L) in serum 25-OHD deficient COPD was lower than sufficient COPD (1.550 $\pm$ 0.55 v/s 1.650 $\pm$ 0.58, p=0.45). Mean FEV<sub>1</sub> values increased from 1.55 $\pm$ 0.55 L in patients with mean serum 25-OHD <20 ng/ml to 1.94 $\pm$ 0.74 L in COPD patients with mean serum 25-OHD  $\geq$  40 ng/ml.

Similar study by Paresch Chandra Mohanta *et al.* [23], on correlating the serum vitamin D level and FEV<sub>1</sub>% of predicted in stable COPD patients. In 25-OHD deficiency COPD cases FEV<sub>1</sub>% of predicted was

28.10 $\pm$ 6.17, in 25-OHD insufficiency cases was 35.92 $\pm$ 8.03 and sufficiency cases was 46.10 $\pm$ 11.99. There was very strong positive correlation present between, serum 25-OHD and FEV<sub>1</sub> % of predicted in stable COPD.

We studied the relationship between serum vitamin level and 6 minute walk distance, The mean 6 minutes walk distance decreased as the degree of vitamin D deficiency increases (343.0 $\pm$ 73.22m > 280.66 $\pm$ 89.22 m > 202.14  $\pm$ 73.99m) (P <0.01) (Figure 3). Most of the study population had mMRC grade 4 (Figure 4).

Finally we studied the correlation between serum vitamin D levels and BODE index. In our study BODE index score ranged from 0 to 9. Most of the patients (60) were having BODE index score < 5. The mean BODE index score increased as the degree of vitamin D deficiency increases. (7.57  $\pm$  1.60 > 3.94  $\pm$  2.10 > 1.96  $\pm$  1.22) (P <0.001) (Figure 5).

Balakrishnan Menon *et al.* [24] studied BODE index in sixty two COPD patients. Staging, severity and exacerbation rate were assessed. Vitamin D levels decreased with increased severity of disease. Mean levels in GOLD severity grade A was 41.02 $\pm$ 14.12, in grade B was 31.57 $\pm$ 12.49, in grade C was 17.63 $\pm$ 8.51 and in grade D was 16.91 $\pm$ 7.89. Vitamin D levels correlated negatively with GOLD severity grade (-0.406), BODE index (-0.408), CCQ (-0.495), exacerbation rate (-0.536) and GOLD staging (-0.369).

## CONCLUSIONS

Our study demonstrated that serum vitamin D deficiency is present in majority of COPD patients. It is more prevalent among patients with higher COPD GOLD Stages. There appears to be a positive correlation between serum vitamin D levels and post bronchodilator FEV<sub>1</sub> (%). Vitamin D deficiency was found to be positively correlated with 6 minutes walk distance and Body mass index (BMI). There is significant correlation between serum vitamin D deficiencies and BODE index.

There is a need of research for supplementation of vitamin D in deficient COPD patients and improvement in respiratory, systemic parameters.

Limitations of this study include small sample size, conducted in a single center. Large sample size, prospective study with supplementation of vitamin D in those who are deficient and assessment of all parameters will provide adequate data to recommend routine assessment and supplementation of this vitamin in all patients.

REFERENCES

1. World Health Report. Geneva: World Health Organization. Available from URL:<http://www.who.int/whr/2000/en/statistics.htm>;2000.
2. World Health Organization. Burden of COPD. Available from URL:<http://www.who.int/respiratory/copd/burden/en>.
3. Salvi S, Agrawal A. India needs a national COPD prevention and control programme.2012.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patient's with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*. 2004; 23:932–46.
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Annals of internal medicine*. 2005 Feb 15;142(4):233-9.
6. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follows up study among the Finnish cohorts of the Seven Countries Study. *Thorax*. 2001 Sep 1; 56(9):703-7.
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'hara P, Owens GR. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. *Jama*. 1994 Nov 16; 272(19):1497-505.
8. Downs SH, Schindler C, Liu LJ, Keidel D, Bayer-Oglesby L, Brutsche MH, Gerbase MW, Keller R, Künzli N, Leuenberger P, Probst-Hensch NM. Reduced exposure to PM10 and attenuated age-related decline in lung function. *New England Journal of Medicine*. 2007 Dec 6; 357(23):2338-47.
9. Krzyzanowski M, Jedrychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of copd in a 13-year follow-up of the Cracow study. *Am Rev Respir Dis* 1986; 134: 1011–1019.
10. Adrian F Gombart. The Vitamin D–antimicrobial Peptide Pathway and Its Role in Protection against Infection. *Future Microbiol*. 2009; 4(9):1151-1165.
11. Lee WJ, Cha HW, Sohn MY, Lee SJ, Kim do W, Vitamin D increases expression of cathelicidin in cultured sebocytes. *Epub* 2012 Jun 14; 304(8):627-32.
12. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2007; 167:1730–7.
13. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr* 2008; 87:1080S–6S.
14. Sundar IK, Rahman I. Vitamin D and susceptibility of chronic lung diseases: role of epigenetics. *Frontiers in pharmacology*. 2011 Aug 30;2:50.
15. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. *Chest*. 2005 Dec 1; 128(6):3792-8.
16. Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007; 357: 266–81.
17. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. *Chest*. 2005 Dec 1; 128(6):3792-8.
18. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *New England Journal of Medicine*. 2004 Mar 4; 350(10):1005-12.
19. Cote C, Celli B. Effect of exacerbations of COPD on multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity, BODE Index. *Chest* 2004:840S.
20. Chong WF, Ong KC, Soh C, Tan SP, Earnest A, Heng BH, Cheah J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in predicting hospitalization for chronic obstructive pulmonary disease. *Chest*. 2004 Oct 1; 126(4):841S.
21. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buyschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. *Thorax*. 2010 Mar 1; 65(3):215-20.
22. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. *Chest*. 2005 Dec 1;128(6):3792-8.
23. Franchi-Abella S. Scientific Session 1: Foetal and Neuroimaging. *Pediatr Radiol*. 2009;39(3):S508-47.
24. Menon B, Mittal A, Nima G, Kaur C, Mittal U, Dogra V. Evaluation of vitamin D levels in COPD and its correlation with disease severity and frequency of exacerbations. *European Respiratory Journal*. 2014 Sep 1;44(Suppl 58):P3960.